Two Sigma Advisers’s Palisade Bio PALI Stock Holding History

Two Sigma Advisers’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-14	Closed	-$14K	–	2862
2021 Q4	$14K	Buy	+14	New	+$24.5K	﹤0.01%	2561

Other funds holding PALI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SWIG

Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers's PALI Position: Q1 2022 in Review

Two Sigma Advisers sold out of Palisade Bio (PALI) in Q1 2022, closing a stake of 14 shares — an estimated $14K sold.

Two Sigma Advisers first reported a position in PALI in Q4 2021 and held it in 1 quarter. The position peaked at $14K in Q4 2021. 18 funds tracked by Wall St. Rank hold PALI as of Q1 2022.

Two Sigma Advisers reported no remaining Palisade Bio position as of Q1 2022 after selling out during the quarter.
Two Sigma Advisers sold 14 Palisade Bio shares in Q1 2022, an estimated $14K.
Two Sigma Advisers first reported a position in Palisade Bio in Q4 2021 and held it in 1 quarter.
Two Sigma Advisers's Palisade Bio position peaked at $14K in Q4 2021.
18 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.